Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04894825

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Advanced Unresectable Solid Tumors Clinical Trial

Official title:
A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Clinical Trial Summary

M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Advanced Unresectable Solid Tumors
  • Neoplasms
Clinical Trial Details
NCT number NCT04894825
Study type Interventional
Source FutureGen Biopharmaceutical (Beijing) Co., Ltd
Contact Zhaoyu Jin, Ph.D
Phone 010-60709130
Email pr@futuregenbiopharm.com
Status Recruiting
Phase Phase 1
Start date June 11, 2021
Completion date December 30, 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02508441 - Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors Phase 1
Active, not recruiting NCT02428712 - A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Phase 1/Phase 2